Abstract: Described are pro-coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays or fragment complementary luciferase. The disclosed pro-coelenterazine analogues provide increased serum stability for live cell assays, and are capable of tuning the brightness and assay windows as needed for the applications.

Abstract: Described are pro-coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays or fragment complementary luciferase. The disclosed pro-coelenterazine analogues provide increased serum stability for live cell assays, and are capable of tuning the brightness and assay windows as needed for the applications.

Abstract: The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.

Abstract: The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.

Abstract: The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.

Abstract: The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.

Abstract: Disclosed is a method of expressing enzymatically-active, recombinant proteolytic tryptase in a eukaryotic host cell, expression constructs which drive the production of enzymatically-active tryptase in transformed hosts, and genetically-engineered eukaryotic host cells containing the expression constructs and which express enzymatically-active proteolytic tryptases. Uses for the proteolytic tryptases so produced are also disclosed. Also disclosed is a method of making active site mutants of proteolytic tryptases in a eukaryotic host cell, expression constructs which drive the production of the mutants in transformed eukaryotic host cells, and genetically-engineered eukaryotic host cells containing the expression constructs and which express the active-site mutated form of proteolytic tryptases.

Abstract: The invention is directed to synthetic polypeptide substrates for tryptase enzymes and assays for tryptase activity that utilize the synthetic polypeptide substrates. The preferred synthetic polypeptide substrates are tetramers of the formula P4-P3-P2-P1, wherein the substrate is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7).

Abstract: The invention is directed to synthetic polypeptide substrates for tryptase enzymes and assays for tryptase activity that utilize the synthetic polypeptide substrates. The preferred synthetic polypeptide substrates are tetramers of the formula P4-P3-P2-P1, wherein the substrate is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7).

Abstract: Disclosed is a method of expressing enzymatically-active, recombinant human &bgr;-tryptase in a yeast host cell, expression constructs which drive the production of enzymatically-active tryptase in transformed yeast, and genetically-engineered yeast containing the expression constructs and which express enzymatically-active human &bgr;-tryptase. Uses for the tryptase so produced are also disclosed.

Abstract: Disclosed is a method of diagnosing or monitoring interstitial cystitis or bladder cancer in a mammal. The method comprises analyzing urine of the mammal for the concentration of a urine-soluble protein selected from the group consisting of neurotrophin-3, nerve growth factor, glial cell line-derived neurotrophic factor, tryptase, and combinations thereof.

Abstract: The disclosure describes highly specific tryptase polyclonal antibodies, and a method to purify the antibodies. Specifically, the invention relates to polyclonal antibodies which have the capacity to capture tryptase out of solution, a process to generate the antibodies, and an enzyme-linked immunosorbent assay (ELISA) for human tryptase which utilizes the antibodies.

Abstract: The disclosure describes highly specific tryptase polyclonal antibodies, and a method to purify the antibodies. Specifically, the invention relates to polyclonal antibodies which have the capacity to capture tryptase out of solution, a process to generate the antibodies, and an enzyme-linked immunosorbent assay (ELISA) for human tryptase which utilizes the antibodies.